Skip to main content
. Author manuscript; available in PMC: 2024 Sep 20.
Published in final edited form as: Curr Top Microbiol Immunol. 2024 Jan 1;445:257–313. doi: 10.1007/82_2021_248

Table 3. Proportion of subjects developing symptoms or signs of disease in S. flexneri 2a (Porter et al. 2018) and S. sonnei CHIMs (Frenck et al. 2020).

Symptom/sign S. flexneri 2a, 2457T S. sonnei, 53G a
Diarrhea 75.9 70.0
Fever 50.0 23.9
Nausea 46.3 30.4
Abdominal pain/cramps 81.5 69.6
Malaise 57.4 43.4
Headache 66.7 69.6
Myalgia 42.6 47.8
Arthralgia 20.4 26.1
Anorexia 64.8 41.3
Vomiting 24.1 19.6
Dysentery 27.8 43.4
a

Excludes subjects receiving 500 CFU dose